Middle East and Africa Medical Foods for Inborn Errors of Metabolism Market, By Products (Amino Acid, Low Protein Food, Glytactin with GMP Amino Acid-Modified Infant Formula with Iron, Low-Calcium/Vitamin D-Free Infant Formula with Iron, Others), Age Group (Infants, Weaning, Adolescent, Adults), Diseases (Phenylketonuria (PKU), Tyrosinemia Types I and II, Maple Syrup Urine Disease (MSUD), Homocystinuria, Glutaric Acidemia Type I, Urea Cycle Disorders, Methylmalonic Acidemia, Isovaleric Acidemia, Organic Acidurias, Renal Disease, Propionic Acidemia, Disorders of Leucine Metabolism, Others), Form (Powder, Liquids, Others), Packaging (Can, Packets, Bottle, Jar, Others), Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Drugs Stores, Online Pharmacies, Others) – Industry Trends and Forecast to 2030.
Middle East and Africa Medical Foods for Inborn Errors of Metabolism Market Analysis and Size
For an individual with a particular genetic condition, nutritional therapy for inborn errors of metabolism meets between 85% and 90% of their nutritional needs. These supplements have negligible adverse effects, making them suitable for use by patients of all ages. Private medical insurance in the U.S. and a few other nations have recently started to provide reimbursement programmes for the use of specific medical foods. Therefore, the increasing adoption of medical foods and nutrient supplements enhances the market growth.
Data Bridge Market Research analyses a growth rate in the medical foods for inborn errors of metabolism market in the forecast period 2023-2030. The expected CAGR of medical foods for inborn errors of metabolism market is tend to be around 6.70% in the mentioned forecast period. The market is valued at USD 103.8 million in 2022, and it would grow upto USD 174.39 million by 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Middle East and Africa Medical Foods for Inborn Errors of Metabolism Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015 - 2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Products (Amino Acid, Low Protein Food, Glytactin with GMP Amino Acid-Modified Infant Formula with Iron, Low-Calcium/Vitamin D-Free Infant Formula with Iron, Others), Age Group (Infants, Weaning, Adolescent, Adults), Diseases (Phenylketonuria (PKU), Tyrosinemia Types I and II, Maple Syrup Urine Disease (MSUD), Homocystinuria, Glutaric Acidemia Type I, Urea Cycle Disorders, Methylmalonic Acidemia, Isovaleric Acidemia, Organic Acidurias, Renal Disease, Propionic Acidemia, Disorders of Leucine Metabolism, Others), Form (Powder, Liquids, Others), Packaging (Can, Packets, Bottle, Jar, Others), Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Drugs Stores, Online Pharmacies, Others)
|
|
Countries Covered
|
Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA)
|
|
Market Players Covered
|
Nestlé Health Science (Switzerland), Nutricia (Netherlands), Solace Nutrition (U.S.), Abbott (U.S.), Mead Johnson andCompany, LLC.(U.S.), BioMarin Pharmaceutical (U.S.), Ajinomoto Cambrooke, Inc. (U.S.), Poa Pharma (Sweden), PKU-MDmil (U.S.), Dr.Schar AG/SPA Primus Pharmaceuticals, Inc. (Italy), Pristine Organics Pvt. Ltd. (India), APR (U.S.), Ener-G foods, INC (U.S.) and Promin Metabolics (U.K.)
|
|
Market Opportunities
|
|
Market Definition
Inborn metabolic errors are the type of disorders in which the body fails to convert food into energy. In case of inborn errors of metabolism, medical foods are widely used as treatment options, and the products accessible in the market are regulated under authoritative and regulatory food and diet supplement statuses. There is no specific enzyme production, which is mainly responsible for breaking down certain substances due to gene mutations.
Middle East and Africa Medical Foods for Inborn Errors of Metabolism Market Dynamics
Drivers
- Increase in Preference for Dietary Supplements
Nutraceutical supplements and foods recommended for medicinal purposes are becoming increasingly popular than enzyme-based therapeutic medications. The inclination from medications to dietary supplements and medicinal foods is most likely because of increasing healthcare costs and customers' preference for inexpensive, quick, and efficient disease management methods. Therefore, this factor increases the growth of the market.
- Increasing Use of Medical Foods
Medical foods are used as the ultimate treatment options for inborn metabolic errors, and the products available on the market are regulated under regulatory food and diet supplement statuses. The nutritional treatment for inherited metabolic errors meets between 85% and 90% of a person's nutritional needs. Additionally, these supplements have nearly no side effects, making them appropriate for patients of all age groups. Presently, private medical insurers in the U.S. and a few other countries have begun to provide reimbursement programmes for the consumption of certain medical foods. Therefore, increasing adoption of medical food and nutrient supplements is anticipated to boost the market growth during the forecast period 2023-2030. This factor improves the market growth.
Opportunities
- Increased Product Launches and Agreements
There has been increasing product launches and agreements between market players,ncreasing the market's growth. For instance, Nutricia opened a sustainable plant in Netherlands in March 2019. The Nutricia Cuijk plant was a huge investment and has increased the volume of specialized infant formula and the market's revenue generation. Furthermore, in June, Mead Johnson andCompany, LLC. announced the merger with Reckitt Benckiser Group plc (RB). It was anticipated that the Mead Johnson brand and business continued to grow with Reckitt Benckiser plc groups’ good innovation and marketing process. Thus, this factor created much opportunity for the market growth.
Restraints/Challenges
- Inadequate Reimbursement Policies
Even though several products were launched, but not all the products have been launched at a cheap price. An inadequate reimbursement scenario is anticipated to restrict the use of medical food and decrease the growth of the medical food market during the forecast period 2023-2030. Thus, this hampers the market growth.
This medical foods for inborn errors of metabolism market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the medical foods for inborn errors of metabolism market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Middle East and Africa Medical Foods for Inborn Errors of Metabolism Market Scope
The medical foods for inborn errors of metabolism market is segmented on the basis of products, age group, diseases, form, packaging and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Products
- Amino Acid
- Glytactin with GMP Amino Acid-Modified Infant Formula with Iron
- Low-Calcium/Vitamin D-Free Infant Formula with Iron
- Low Protein Food
- Others
Age Group
- Infants
- Weaning
- Adolescent
- Adults
Diseases
- Phenylketonuria (PKU)
- Maple Syrup Urine Disease (MSUD)
- Homocystinuria
- Methylmalonic Acidemia
- Organic Acidurias
- Propionic Acidemia
- Isovaleric Acidemia
- Disorders of Leucine Metabolism
- Glutaric Acidemia Type I Renal Disease
- Tyrosinemia Types I and II
- Urea Cycle Disorders
- Others
Forms
- Powder
- Liquids
- Gels and Others
Packaging
- Can
- Jar
- Packets
- Bottle
- Others
Distribution Channel
- Retail Pharmacies
- Hospital Pharmacies
- Drugs Stores
- Online Pharmacies
- Others
Medical Foods for Inborn Errors of Metabolism Market Regional Analysis/Insights
The medical foods for inborn errors of metabolism market is analyzed and market size insights and trends are provided by mechanism, category, treatment, software, services, app accessibility, app type, application, patients as referenced above.
The major countries covered in the medical foods for inborn errors of metabolism market report are Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA).
Saudi Arabia is anticipated to grow with the highest CAGR in the forecast period because of increased healthcare expenditure in this region and patient are more shifted in taking medical food rather than enzymatic therapy. Disposable income is high through which it is feasible for the patients to afford the medical foods in their regular diet.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of Middle East and Africa brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Middle East and Africa Medical Foods for Inborn Errors of Metabolism Market Share Analysis
The medical foods for inborn errors of metabolism market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, Middle East and Africa presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to medical foods for inborn errors of metabolism market.
Key players operating in the medical foods for inborn errors of metabolism market include:
- Nestlé Health Science (Switzerland)
- Nutricia (Netherlands)
- Solace Nutrition (U.S.)
- Abbott (U.S.)
- Mead Johnson andCompany, LLC.(U.S.)
- BioMarin Pharmaceutical (U.S.)
- Ajinomoto Cambrooke, Inc. (U.S.)
- Poa Pharma (Sweden)
- PKU-MDmil (U.S.)
- Dr.Schar AG/SPA Primus Pharmaceuticals, Inc. (Italy)
- Pristine Organics Pvt. Ltd. (India)
- APR (U.S.)
- Ener-G foods, INC (U.S.)
- Promin Metabolics (U.K.)
SKU-